Baricitinib

Common brands: Olumiant, Methotrexate, Rasuvo, Trexall, Jylamvo

Top reporter: Eli Lilly And Company

Janus Kinase Inhibitor [EPC]Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Tumor Necrosis Factor Blocker [EPC]Interleukin-6 Receptor Antagonist [EPC]
9,396
Total Reports
6,396
Serious Reports
868
Death Reports
30
Reported Reactions
Death Report Ratio: High (9.24%)

Patient Demographics

Male
2,787
Female
5,716

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Baricitinib.

# Reaction Reports % of Total
1 DRUG INEFFECTIVE 732
10.7%
2 OFF LABEL USE 667
9.7%
3 COVID-19 447
6.5%
4 RHEUMATOID ARTHRITIS 352
5.1%
5 PULMONARY EMBOLISM 302
4.4%
6 PNEUMONIA 274
4.0%
7 HEADACHE 261
3.8%
8 HERPES ZOSTER 239
3.5%
9 DEATH 235
3.4%
10 NAUSEA 228
3.3%
11 DEEP VEIN THROMBOSIS 213
3.1%
12 FATIGUE 185
2.7%
13 WEIGHT INCREASED 184
2.7%
14 ARTHRALGIA 181
2.6%
15 THERAPY INTERRUPTED 178
2.6%
16 URINARY TRACT INFECTION 176
2.6%
17 DYSPNOEA 174
2.5%
18 PAIN 174
2.5%
19 DIARRHOEA 167
2.4%
20 CONDITION AGGRAVATED 162
2.4%
21 RASH 156
2.3%
22 ALOPECIA 150
2.2%
23 VOMITING 145
2.1%
24 INFECTION 137
2.0%
25 PYREXIA 135
2.0%
26 PAIN IN EXTREMITY 127
1.9%
27 FALL 123
1.8%
28 COUGH 118
1.7%
29 DIZZINESS 117
1.7%
30 SINUSITIS 116
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.